)
Visual21 Nov 2025
Data center suppliers
CNS Pharmaceuticals (CNSP) investor relations material
CNS Pharmaceuticals Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary14 Nov, 2025
Executive summary
Focused on developing anti-cancer drug candidates for CNS tumors, with lead assets TPI 287 and Berubicin targeting Glioblastoma and other malignancies.
TPI 287 and Berubicin have Orphan Drug Designation from the FDA, providing potential market exclusivity.
March 2025 topline data for Berubicin showed no statistically significant difference in overall survival versus standard of care, but comparable outcomes and ongoing evaluation of next steps.
Exclusive license agreement for TPI 287 signed with Cortice Biosciences in July 2024, with milestone and royalty obligations.
Financial highlights
Net loss for Q3 2025 was $3.2 million, down from $5.6 million in Q3 2024; nine-month net loss was $9.9 million, down from $11.7 million year-over-year.
General and administrative expenses for Q3 2025 were $1.1 million, down from $1.4 million in Q3 2024; R&D expenses were $2.2 million, down from $4.2 million.
Cash and cash equivalents as of September 30, 2025, were $9.9 million, up from $6.5 million at year-end 2024.
Working capital at quarter-end was $9.4 million.
Outlook and guidance
Estimated working capital sufficient to fund operations into the second half of 2026, assuming core expense run rate of $5.5 million/year.
TPI 287 trial expected to initiate in Q2 2026, with estimated trial cost of $12–15 million, requiring significant additional financing.
No commitments for additional financing; may need to raise funds through equity or debt.
Berubicin: What are the next steps with the FDA?
TPI 287 trial funding strategy and timeline?
Nasdaq listing risk from bid price compliance?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next CNS Pharmaceuticals earnings date
Q4 202531 Mar, 2026
Next CNS Pharmaceuticals earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
CNS Pharmaceuticals Inc. is a clinical-stage pharmaceutical company engaged in the development of anti-cancer drug candidates. Its primary focus is on treatments for primary and metastatic cancers of the brain and central nervous system malignancies. The company's flagship drug candidate, Berubicin, is a novel anthracycline, notable for being the first of its kind to cross the blood-brain barrier. This drug is currently in development for the treatment of glioblastoma multiforme (GBM), a particularly aggressive and currently incurable form of brain cancer. In addition to Berubicin, CNS Pharmaceuticals is advancing WP1244, a drug technology that leverages anthracycline and distamycin-based scaffolds to create potent small molecule agents. The company is headquartered in Houston, Texas, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage